Qiagen snares key assets of two biotech companies

Dutch biotech Qiagen is buying up the key assets of two biotech firms for up to $18 million. The bulk of that goes to buy the assets of LumiCyte in Fremont, California. LumiCyte makes protein analysis tools. Qiagen is also buying the bioanalytical assets of SuNyx, a German biotech that markets bioanalytic solutions to the biopharma industry.

- read this press release and this press release for more on both